Barclays upgrade Ionis Pharmaceuticals (Ions) stock is Pt

IO Pharmaceuticals, Inc. (NASDAQ:ion) is one of 11 intermediate cap healthcare stocks to buy according to hedge funds. Barclays upgraded from “equal weight” to “overweight” with a price target of $51 ahead of its $57 price target, the Tryngolza Phase 3 Core/Core2 data. Flies. The company expects a trial to have a greater than 90% chance of colliding with the primary endpoint, and expects it to be likely to hit all important second biomarker endpoints.

A lab scientist who makes groundbreaking discoveries in biotechnology.

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) has announced that its partner Biogen will share positive top-line results from a Phase 1 study of Saranelsen (ION306/BIIB115), an investigative antisense oligonucleotide (ASO) being developed for the potential treatment of spinal myophytic myobiology (SMA). While exploiting the same mechanism of action as Spinraza® (Nusinersen), but designed to achieve greater efficacy, Salanersen can achieve higher efficacy and allow for once a year. In the first quarter of 2025, Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) revenues increased 10% compared to the same period last year.

Although we acknowledge the potential of Aeon as an investment, we believe certain AI stocks offer a greater reverse chance, pose a risk of decline. If you’re looking for a highly undervalued AI stock that can make a significant profit from the tariff and supervision trends of the Trump era, check out our free report. Best Short-Term AI Stocks.

Read next: Analysts say they buy 13 cheap AI stocks and 11 unstoppable growth stocks are currently investing

Disclosure: None. This article was originally published Insider Monkey.